Covance Finalizes Merck Deal, Delays Construction of Preclinical Unit

Thursday, August 20, 2009 06:35 AM

Covance officially closed a deal with Merck earlier this week to provide genomics analysis services to the drug developer for the next five years. Under the terms of the $145-million agreement, the contract research organization (CRO) acquired Merck’s Seattle-based Gene Expression Laboratory. All Merck employees related to the Seattle facility became Covance employees as of August 17.

Covance also announced this week that it is delaying plans to construct a $145-million preclinical toxicology testing facility in Virginia, a site that was purchased from Eli Lilly in 2007. Construction will be delayed for up to two years, Covance said. In its Q2 2009 financial statement, released in July, the company attributed a drop in early-stage revenues to a drop in preclinical demand.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs